Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Common pitfalls and tips and tricks to get the most out of your transpulmonary thermodilution device: results of a survey and state-of-the-art review.

Hofkens PJ, Verrijcken A, Merveille K, Neirynck S, Van Regenmortel N, De Laet I, Schoonheydt K, Dits H, Bein B, Huber W, Malbrain ML.

Anaesthesiol Intensive Ther. 2015;47(2):89-116. doi: 10.5603/AIT.a2014.0068. Epub 2014 Nov 25. Review.

2.

Substance use and misuse in persons with intellectual disabilities (ID): results of a survey in ID and addiction services in Flanders.

To WT, Neirynck S, Vanderplasschen W, Vanheule S, Vandevelde S.

Res Dev Disabil. 2014 Jan;35(1):1-9. doi: 10.1016/j.ridd.2013.10.015. Epub 2013 Nov 8.

PMID:
24211791
3.

Targeted interactomics reveals a complex core cell cycle machinery in Arabidopsis thaliana.

Van Leene J, Hollunder J, Eeckhout D, Persiau G, Van De Slijke E, Stals H, Van Isterdael G, Verkest A, Neirynck S, Buffel Y, De Bodt S, Maere S, Laukens K, Pharazyn A, Ferreira PC, Eloy N, Renne C, Meyer C, Faure JD, Steinbrenner J, Beynon J, Larkin JC, Van de Peer Y, Hilson P, Kuiper M, De Veylder L, Van Onckelen H, Inzé D, Witters E, De Jaeger G.

Mol Syst Biol. 2010 Aug 10;6:397. doi: 10.1038/msb.2010.53.

4.

AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis.

Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, Watkins B, Sonis S, Coulie B, Rottiers P.

Oral Oncol. 2010 Jul;46(7):564-70. doi: 10.1016/j.oraloncology.2010.04.008. Epub 2010 Jun 9.

PMID:
20542722
5.

Characterization of ApuB, an extracellular type II amylopullulanase from Bifidobacterium breve UCC2003.

O'Connell Motherway M, Fitzgerald GF, Neirynck S, Ryan S, Steidler L, van Sinderen D.

Appl Environ Microbiol. 2008 Oct;74(20):6271-9. doi: 10.1128/AEM.01169-08. Epub 2008 Aug 8.

6.

Delivery of therapeutic proteins through Lactococcus lactis.

Neirynck S, Steidler L.

Biotechnol Genet Eng Rev. 2006;22:253-66. Review. No abstract available.

PMID:
18476334
7.

Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.

Waeytens A, Ferdinande L, Neirynck S, Rottiers P, De Vos M, Steidler L, Cuvelier CA.

Inflamm Bowel Dis. 2008 Apr;14(4):471-9.

PMID:
18092343
8.

Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.

Termont S, Vandenbroucke K, Iserentant D, Neirynck S, Steidler L, Remaut E, Rottiers P.

Appl Environ Microbiol. 2006 Dec;72(12):7694-700. Epub 2006 Oct 6.

9.

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L.

Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9. Epub 2006 May 22.

PMID:
16716759
10.

Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10.

Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP.

Eur J Pharm Biopharm. 2005 Aug;60(3):349-59.

PMID:
15927456
11.

Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis.

Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP.

Eur J Pharm Biopharm. 2005 Jan;59(1):9-15.

PMID:
15567296
12.

Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.

Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L.

Gastroenterology. 2004 Aug;127(2):502-13.

PMID:
15300583
13.

A "universal" human influenza A vaccine.

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W.

Virus Res. 2004 Jul;103(1-2):173-6. Review.

PMID:
15163506
14.

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.

Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E.

Nat Biotechnol. 2003 Jul;21(7):785-9. Epub 2003 Jun 15.

PMID:
12808464
15.

Soluble recombinant influenza vaccines.

Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1961-3. Review.

16.

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E.

Science. 2000 Aug 25;289(5483):1352-5.

17.

A universal influenza A vaccine based on the extracellular domain of the M2 protein.

Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W.

Nat Med. 1999 Oct;5(10):1157-63.

PMID:
10502819
18.

Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin.

Saelens X, Vanlandschoot P, Martinet W, Maras M, Neirynck S, Contreras R, Fiers W, Jou WM.

Eur J Biochem. 1999 Feb;260(1):166-75.

19.

Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase.

Martinet W, Saelens X, Deroo T, Neirynck S, Contreras R, Min Jou W, Fiers W.

Eur J Biochem. 1997 Jul 1;247(1):332-8.

20.

Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells.

Vanlandschoot P, Beirnaert E, Neirynck S, Saelens X, Jou WM, Fiers W.

Arch Virol. 1996;141(9):1715-26.

PMID:
8893793

Supplemental Content

Loading ...
Support Center